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Abstract
Background: Colorectal cancer is third most common malignancy and is the second most common cause of
cancer-related death. The MUC1 heterodimeric protein is aberrantly overexpressed in colorectal cancer and has
been linked to poor outcomes in this disease. Here, we investigate the effects of the MUC1-C subunit inhibitor
(GO-203), which disrupts MUC1-C homo-oligomerization, on human colorectal cancer cells.
Methods: TIGAR mRNA level was determined using qRT-PCR. Western blotting was used to measure TIGAR
protein level and AKT-mTOR-S6K1 pathways. Reactive oxygen species and apoptosis were measured by flow
cytometry. Effect of MUC1-C peptide, GO-203 was studied on colorectal xenograft tumors. Immunohistochemistry was
utilized for TIGAR staining.
Results: Treatment of MUC1-overexpressing SKCO-1 and Colo-205 colon cancer cells with GO-203 was associated with
downregulation of the TP53-inducible glycolysis and apoptosis regulator (TIGAR) protein. TIGAR promotes the shunting
of glycolytic intermediates into the pentose phosphate pathway and thus is of importance for maintaining
redox balance. We show that GO-203-induced suppression of TIGAR is mediated by inhibition of AKT and the
downstream mTOR pathway. The results also demonstrate that targeting MUC1-C blocks eIF4A cap-dependent translation
of TIGAR. In concert with these results, GO-203-induced suppression of TIGAR was associated with decreases
in GSH levels. GO-203 treatment also resulted in increases in reactive oxygen species (ROS) and loss of mitochondrial
transmembrane potential. Consistent with these results, GO-203 inhibited the growth of colon cancer cells in vitro and
as xenografts in nude mice. Inhibition of MUC1-C also downregulated TIGAR expression in xenograft tissues.
Conclusions: These findings indicate that MUC1-C is a potential target for the treatment of colorectal cancer.
Colorectal cancer patients who overexpress MUC1-C may be candidates for treatment with the MUC1-C inhibitor alone
or in combination therapy with other agents.
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Background
Colorectal cancer (CRC) is the third most common
cancer in the world. CRC is the fourth leading cause
of cancer-related mortality, causing over 600,000
deaths per year. Colorectal cancer is the most common
cancer in 40 European countries [1]. A large number of
genetic and epigenetic alterations that lead to malignant
transformation have been identified in colorectal cancer.
These include alterations in genes involved in chromo-
somal and microsatellite instability. More than 50% of
newly diagnosed colorectal cancer patients present with
some type of metastasis [1]. The Wnt/β-catenin signaling
pathway is of importance for the development of colo-
rectal cancer with more than 80% mutation in APC
(adenomatous polyposis coli) and about 5% activating
mutations in β-catenin [2, 3]. The proliferation and
differentiation of intestinal stem and progenitor cells
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is regulated by Wnt signaling. Mutations in APC and
β-catenin are among the earlier events that lead to
hyperplasia in the intestinal crypts leading to colorectal
cancer development [4, 5]. Moreover, Wnt signaling
is required for colorectal cancer progression and me-
tastasis [6].
MUC1 (mucin 1) is a heterodimeric glycoprotein
expressed on the apical surface of normal epithelium and is
overexpressed in diverse cancers [7]. MUC1 is translated as
a single polypeptide and is processed by auto-cleavage into
two subunits that form a stable heterodimeric complex at
the cell membrane. The N-terminal subunit of MUC1
(MUC1-N) contains variable numbers of 20 amino acid
tandem repeats that are glycosylated on serine and threo-
nine. The MUC1 C-terminal subunit (MUC1-C) is com-
posed of a 58 amino acid extracellular domain, a 28 amino
acid transmembrane domain and a 72 amino acid cyto-
plasmic domain (MUC1-CD) [7]. MUC1-N is attached
to MUC1-C on the apical border of normal epithelial
cells. Shedding of MUC1-N from the cell surface frees
MUC1-C to function as a putative receptor inside the
cell in response to stress [7]. Importantly, the MUC1-C
cytoplasmic domain is sufficient for transformation [8].
MUC1-C interacts with diverse effectors, such as β-
catenin [9], IKK β [10], and NFkB p65 [11], which have
been linked to transformation. Wnt and NFkB signaling
pathways are known to be activated in colorectal cancer
[12, 13]. Incorporation of MUC1-C into the outer mito-
chondrial membrane also inhibits stress-induced loss of
the mitochondrial transmembrane potential [14]. Overex-
pression of MUC1 in human cancers blocks the induction
of apoptosis and necrosis in response to DNA damaging
agents [15], reactive oxygen species [16, 17] and hypoxia
[18]. MUC1 is known to be overexpressed in human colo-
rectal cancer cells [19]. The MUC1 oncoprotein is predict-
ive for tumor progression in colorectal cancers [20],
including those related to HNPCC (Hereditary nonpoly-
posis colorectal cancer) [21]. The overexpression of MUC1
predominates at the invasive front [20]. A positive correl-
ation has been described between mucin secretion, prolifer-
ation, invasiveness, metastasis and poor prognosis [21, 22].
Overexpression of MUC1 is more pronounced at the dee-
pest tumor invasive portion, lymphatic and venous inva-
sion, and lymph node and liver metastasis [23]. Correlation
of MUC1 with poor prognosis has been reported in mis-
match repair gene colorectal tumors but not in MLH1
negative tumors or in Lynch syndrome (HNPCC) [24].
Research on MUC1 as a target in colorectal cancer has
been focused on the development of a vaccine [25, 26].
However, there are no available small molecules or peptides
that target MUC1 for treating MUC1-positive colorectal
cancers. MUC1-C contains CQC residues in the cytoplas-
mic domain that are important for its homodimerization
and function as an oncoprotein [27]. Accordingly, direct
inhibitors of MUC1-C, designated GO-201/GO-203 have
been developed to block the CQC motif [28].
Protein translation is a tightly regulated process that is
regulated by translation initiation. This initiation step is
controlled by the initiation factors (elF4F) complex at the
ribosomal recruitment [29]. The elF4F complex is formed
by the binding of elF4E to the 5′ cap of mRNAs and
recruitment of elF4G and elF4A. The PI3K-AKT signaling
pathway is a major regulator of protein translation which is
upstream to the mammalian target of rapamycin complex 1
(mTORC1). mTORC1 activates 40S ribosomal protein S6
kinases (S6Ks) which contribute to cap-dependent transla-
tion that, in turn, enhance the eIF4A RNA helicase activity
[29]. S6K induces degradation of the tumor suppressor
programmed cell death protein 4 (PDCD4), which is an
eIF4A inhibitor [30]. eIF4A initiates translation by
unwinding highly structured 5′ untranslated regions
(UTRs) in mRNAs, such as those encoding cyclin D1 and
MYC [31]. In this way, tumor cells can regulate transla-
tion in response to growth signals through mTORC1-
induced activation of the eIF4A RNA helicase function.
The present study demonstrates that treatment of human
colorectal cancer cell lines with the MUC1-C inhibitor
GO-203 is associated with downregulation of the
AKT→mTOR pathway and suppression of cap-dependent
translation of the TIGAR (TP53-induced glycolysis and
apoptosis regulator) protein. Targeting MUC1-C with
GO-203, in turn, results in disruption of redox balance and
inhibition of growth, supporting the notion that MUC1-C
is a potential target for the treatment of colorectal cancer.
Methods
Cell culture
Human SW480 and LOVO colorectal cancer cells were
grown in DMEM (Cellgro) containing 10% heat-inactivated
fetal bovine serum, 100 μg/ml streptomycin, 100 units/ml
penicillin and 2 mmol/l L-glutamine. Human COLO-205
colon cancer cells were cultured in RPMI (ATCC) con-
taining 10% heat-inactivated fetal bovine serum 100 μg/ml
streptomycin, 100 units/ml penicillin and 2 mmol/L-glu-
tamine. Authenticity of the cells was confirmed by short
tandem repeat (STR) analysis. Mycoplasma contamination
testing was done using kit (MycoAlert, Lonza). The cells
were treated with GO-203 and control peptide CP-2
(Genus Oncology, Boston) as described [7]. Cells were
treated with the PI3K inhibitor LY294002 (Cayman Chem-
ical Company), rapamycin (Cell Signaling Technology),
AKT inhibitor GSK690693 (Selleck Chemicals) and Silves-
trol was gift from Prof John A. Porco, Jr [32].
Quantitative RT-PCR
For qRT-PCR analysis, cDNA synthesis was performed with
1 μg total RNA using the High Capacity Reverse Transcrip-
tion Kit (Applied Biosystems). The cDNA samples were
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amplified using the SYBR Green qPCR assay kit (Applied
Biosystems) and the StepOnePlus real time PCR system
(Applied Biosystems). TIGAR Primers used for qRT-PCR:
Forward 5′ CTCCAGTGATCTCATGAG 3′ Reverse 5′-A
GACACTGGCTGCTAATC 3′. Statistical significance was
determined by the Student’s t test.
Western blotting
Whole cell lysates were prepared as described [11]. Soluble
proteins were analyzed by immunoblotting with anti-
MUC1-C (Ab5; Thermo Scientific), anti-TIGAR (Abcam),
anti-p-Akt, anti-Akt, anti-p-S6K1, anti-S6K1, anti-PDCD4
(Cell signaling Technology) and anti-β-actin (Sigma).
Reactivity was detected with horseradish peroxidase-
conjugated secondary antibodies and chemilumines-
cence (GE healthcare).
Cell viability assay
To assess cell viability, 20,000–30,000 cells were plated
and cultured for 48 h. GO-203 and CP-2 were added at
5 μM every day for six days. Cell viability was measured
by trypan blue exclusion.
Reactive oxygen species (ROS) measurement
Cells were incubated with 5 μM DCFH-DA (Molecular
Probes) for 20 min at 37 °C. Fluorescence of oxidized
DCF was measure at an excitation of 480 nm and an
emission at 525 nm.
Determination of Glutathione (GSH) levels
The levels of GSH in the cells were determined according
to the method [33] based on the formation of 2-nitro-5-
tiobenzoic acid from DTNB in the presence of GSH. In
brief, 25 μl of trichloroacetic acid (15%) was added to
50 μl of the homogenate, followed by centrifugation at
13,000 × g for 5 min at 4 °C. A supernatant aliquot (50 μl)
was mixed with 50 μl of 3.4 mM ethylenediaminetetraace-
tic acid (EDTA) dissolved in PBS, 1 ml of PBS, and 250 μl
of DTNB in PBS (20 mg/ml). The absorbance was mea-
sured at 412 nm after 15 min and compared to a standard
curve of GSH (0.01–0.5 mM).
Mitochondrial membrane potential analysis
Mitochondrial membrane potential was measured using
the JC1 Mitochondrial Membrane Potential Assay Kit
(Abcam) following the manufacturer’s instructions.
Analysis of apoptosis
Cells were fixed with 80% ethanol and incubated in
PBS containing 40 μg/ml RNase and 40 μg/ml propi-
dium iodide. Sub-G1 analysis was determined by flow
cytometry.
Colon tumor xenografts models
Four- to 6-week-old BALB/c nu/nu male/female mice
were injected subcutaneously with 1 × 107 Colo-205 or
SKCO-1 cells in the flank. When tumors were detect-
able, the mice were pair-matched into control and treat-
ment groups of 8 mice each. Mice were excluded if the
tumors were not within 15% of the mean volume. PBS
(control vehicle), 18 mg/kg GO-203, or 18 mg/kg CP-2
(peptides dissolved in PBS) were administered daily by
intraperitoneal injection for 28 days. Tumor volume (V)
was calculated using the formula V = L2 ×W/2, where L
and W are the larger and smaller diameters, respectively.
For SKCO-1 tumor xenografts, Groups of 8 mice each
were treated with PBS (Control), 6 mg/kg GO-203 each
day for 5 days intravenously (iv), or 3 mg/kg GO-203
each day for 5 days iv each week for two weeks.
Immunohistochemistry
Paraffin-embedded blocks of xenograft tumor tissues were
deparaffinized in xylene and rehydrated using a graded
ethanol series. Antigen was retrieved by boiling the slides
in a microwave oven for 15 min in 0.01 mol/l citrate
buffer (pH 6.0). Endogenous peroxidase was blocked with
a 3% H2O2-methanol solution, and the slides were incu-
bated in 10% normal goat serum for 30 min to prevent
non-specific staining. The tissue sections were then incu-
bated overnight at 4 °C with primary antibody [TIGAR sc-
166291 (1:100 dilution); Santa Cruz Biotechnology, Dallas,
TX, USA]. The standard biotin-streptavidin-peroxidase
method was used and the sections were lightly coun-
terstained with hematoxylin. The expression of TIGAR
in tumor tissues was analyzed using the eSlide capture
device (ScanScope CS, Aperio Technologies Inc., Vista,
CA, USA).
Results
Targeting MUC1-C inhibits AKT-mTORC-S6K1 signaling
GO-203 inhibits MUC1-C homodimerization which blocks
its oncogenic function [28]. The effect of GO-203 has not
been studied on the AKT-mTORC-S6K1 translation path-
way. Treatment of SKCO-1 cells with GO-203 was associ-
ated with downregulation of p-AKT (Fig. 1a). The PI3K-
AKT pathway is a major protein synthesis regulator [29].
This pathway is also upstream of the mTORC1 (mamma-
lian target of rapamycin complex 1). mTORC1 transmit
positive signal to activate p70 S6 kinase and participate in
the inactivation of the elF4E inhibitor, 4E-BP1 [29]. GO-
203 inhibited the activation of S6K1 in SKCO-1 cells
(Fig. 1b). Activation of S6K1 leads to the phosphorylation
of PDCD4 at Ser 67 and is subsequently degraded by the
ubiquitin ligase SCF (betaTRCP) [30]. Regulated deg-
radation of PDCD4 in response to oncogene activation
allows efficient protein synthesis and cell growth.
Activation of the elF4A RNA helicase is crucial for the
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initiation of translation. To understand the potential
role of elF4A, we studied the effect of GO-203 on the
expression of the tumor suppressor programmed cell
death protein 4 (PDCD4), which is known to block
elF4A RNA helicase activity [30]. GO-203 treatment
of SKCO1 cells inhibited the degradation of PDCD4
(Fig. 1c). These findings demonstrate that targeting
MUC1-C with GO-203 inhibits AKT-mTORC-S6K1
signaling in colorectal cancer cells.
Inhibition of MUC1-C blocks TIGAR translation
TIGAR (TP53-induced glycolysis and apoptosis regulator)
has been reported to be highly expressed in human colon
cancers with tumorigenic phenotype [34, 35]. Targeting
MUC1-C in hematologic malignancies has been reported
to inhibit TIGAR at the protein level [36, 37]. The
mechanism for TIGAR downregulation is still un-
known. To further understand TIGAR protein inhib-
ition, SKCO-1 cells were treated with GO-203 and
control peptide CP-2. GO-203 treatment was associ-
ated with a marked depletion of TIGAR levels (Fig. 2a,
Left). Interestingly, there was no significant change in
TIGAR mRNA levels between GO-203 and CP-2
treated cells (Fig. 2a, Right), supporting a potential
translational mechanism. To determine whether the
AKT-mTORC-S6K pathway is involved in TIGAR pro-
tein translation, SKCO1 cells were treated with PI3K
inhibitor, LY294002 and Akt inhibitor, GSK690693.
Both inhibitors significantly reduced TIGAR protein
levels (Fig. 2b), indicating that PI3K-AKT is involved
in TIGAR protein synthesis. To assess the potential
role of mTORC, Rapamycin, an inhibitor of mTORC
was used to measure TIGAR levels. Indeed, Rapamycin
treatment inhibited TIGAR levels (Fig. 2c). Silvestrol is
an inhibitor of the translation initiation factor elF4A
RNA helicase [32]. Silvestrol-treated SKCO1 cells
resulted in a significant downregulation of TIGAR
protein (Fig. 2d). These results indicate that GO-203
downregulates TIGAR protein synthesis by inhibiting
the PI3K-AKT-S6K1 pathway.
Effect of GO-203 on glutathione and reactive oxygen
species (ROS)
Treatment of SKCO-1 cells with GO-203 significantly
decreased GSH levels. In contrast, the inactive control
peptide CP-2 had no apparent effect on GSH levels
(Fig. 3a). N-acetylcysteine (NAC) is a precursor for GSH
biosynthesis. We therefore investigated whether NAC al-
ters the GO-203-induced disruption of redox balance.
Indeed, the addition of NAC with GO-203 blocked GSH
depletion (Fig. 3b). As reported previously [16], MUC1-
C blocks the disruption of redox balance and MUC1-C
silencing is associated with increases in reactive oxygen
species (ROS) production. GO-203 treatment of SKCO-
1 cells was associated with a more than 2-fold increase
in ROS production; however, CP-2 had little effect
(Fig. 3c). In addition, GO-203-induced ROS production
was blocked by NAC (Fig. 3d). These results indicate
that MUC1-C inhibition leads to depletion of GSH and
induction of ROS production. Moreover, both of these
effects of GO-203 are reversed by NAC.
Effect of GO-203 on mitochondrial membrane potential
and apoptosis
Disruption of redox balance leads to the loss of mito-
chondrial membrane potential and apoptosis [38]. In this
regard, treatment of SKCO-1 cells with GO-203 resulted
in a significant decrease in mitochondrial membrane
potential (Fig. 4a). To further assess the effects on cell
death, SKCO-1 cells were treated with GO-203 for
3 days. GO-203 treatment was associated with uptake of
propidium iodide due to loss of cell membrane integrity
(Fig. 4b-c). GO-203 induced approximately 80% death of
SKCO-1 cells (Fig. 4b). By contrast, CP-2, had little
effect on cell viability.
Effect of GO-203 on colorectal cancer cell growth
Treatment of MUC1-negative SW480 and LOVO cells
with GO-203 had no effect on cell growth (Fig. 5a). By
contrast, GO-203 significantly inhibited MUC1-positive
COLO-205 cell growth and decreased viable cell number
Fig. 1 GO-203 inhibits AKT-mTORC-S6K1 translation pathway. a-c SKCO-1 cells were treated each day with 5 μM GO-203 or CP-2 for three days
and lysates were immunoblotted with indicated antibodies
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Fig. 2 GO-203 inhibits TIGAR translation. a SKCO-1 cells were treated each day with 5 μM GO-203 or CP-2 for three days and lysates were
immunoblotted with indicated antibodies (Left). TIGAR mRNA levels were determined by qRT-PCR. The results are expressed as relative
TIGAR mRNA levels (mean ± sd of three determinations) compared with that obtained for GAPDH as a control (Right). b SKCO-1 cells were
treated with the PI3K inhibitor LY294002 (50 μM) and Akt inhibitor GSK690693 (10 μM) for 48 h. Cell lysates were immunoblotted with indicated antibodies.
c SKCO-1 cells were treated with Rapamycin (100 nM) for 24 h. Cell lysates were immunoblotted with indicated antibodies. d SKCO-1 cells were treated
with Silvestrol (100 nM) for 24 h. Lysates were immunoblotted with indicated antibodies
Fig. 3 GO-203 disrupts the redox balance. a SKCO-1 cells were treated each day with 5 μM GO-203 or CP-2 for three days. These cells were harvested
and analyzed for GSH levels using the DTNB method. b SKCO-1 cells were treated each day with 5 μM GO-203 or CP-2 for three days. The GO-203
treated cells were also incubated with 5 mM NAC. The cells were analyzed for GSH levels. c SKCO-1 cells were treated with 5 μM GO-203 or CP-2 for
three days. The cells were incubated with DC-FDA, and the fluorescence of oxidized DCF was measured by a microplate reader. d The GO-203 treated
cells were also incubated with 5 mM NAC and ROS generation was measured using DC-FDA. * p < 0.05, ** p < 0.01
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(Fig. 5a). GO-203 has also been reported to inhibit
MUC1- positive SKCO-1 cell proliferation [39]. These
findings demonstrate that the effects of GO-203 on cell
growth and survival are selective for MUC1-expressing
cells. Moreover, GO-203 inhibits MUC1 positive colorec-
tal cancer cell proliferation by decreasing intracellular
GSH levels and enhanced ROS production.
GO-203 induces regression of colon tumors in xenografts
models
To extend these results obtained from in vitro experi-
ments, we established subcutaneous COLO-205 colon
tumor xenografts (~90 mm3) in the flanks of nude mice.
Groups of 8 mice each were treated intraperitoneally (ip)
with PBS (Control), 18 mg/kg GO-203 or 18 mg/kg CP-2
each day for 28 days (Fig. 5b). Compared to the control
group, growth of the COLO-205 tumors was significantly
inhibited in the GO-203-treated mice. Moreover, these
tumors regressed completely by the end of treatment (day
28) and there was no evidence for regrowth by day 180
(Fig. 5b). In contrast to the anti-tumor activity of GO-203,
treatment with CP-2 had no effect on COLO-205 tumor
growth (Fig. 5b). Importantly, GO-203 was not associated
with loss of body weight or other apparent toxicities.
Studies were also performed on established subcutaneous
SK-CO-1 tumor xenografts (~90 mm3) to explore other
GO-203 dose-schedules (Fig. 5c). Groups of 8 mice each
were treated with PBS (Control), 6 mg/kg GO-203 each
day for 5 days intravenously (iv) or 3 mg/kg GO-203 each
day for 5 days iv each week for two weeks. The results
demonstrate that, as compared to the control group,
growth of tumors in the GO-203-treated mice was
inhibited significantly with both dose-schedules (Fig. 5c).
These findings indicate that GO-203 is effective in inhi-
biting growth and survival of MUC1-positive colorectal
cancer cells in mouse xenograft models. Tumor tissues
from the GO-203 and CP-2 treated mice were harvested
and stained for TIGAR. TIGAR levels were decreased sub-
stantially by GO-203 treatment, further confirming that
inhibition of MUC1-C function downregulates TIGAR
expression (Fig. 5d).
Discussion
MUC1 is expressed in colorectal tumors, predominantly
in those with more aggressive disease [19–23]. However,
there has been no direct proof that MUC1 is essential for
colorectal cancer cell growth and survival. Protein synthe-
sis is known to be regulated by PI3K-AKT signaling. AKT
controls translation by activation of mTORC1 that results
in the phosphorylation of p70S6 Kinase [40]. In turn, S6K
phosphorylates and thereby induces the degradation of
PDCD4, an inhibitor of eIF4A RNA helicase activity that
regulates translation of proteins [30]. The present work
demonstrates that targeting MUC1-C with GO-203
inhibits p-AKT in colorectal cancer cells. GO-203 further
blocks the phosphorylation of S6K1. PDCD4 is a down-
stream target of S6K1, which undergoes phosphorylation,
ubiquitination and degradation, contributing to efficient
protein synthesis for growth and survival. GO-203 inhib-
ited the degradation of PDCD4 which inhibits elF4A
helicase activity. Hence these findings demonstrate that
GO-203 regulates AKT-S6K1-elF4A signaling in colorectal
cancer cells.
TIGAR protein has been reported to be overexpressed
in colon cancer [34, 35]. Inhibition of MUC1-C in
hematological malignancies downregulates TIGAR at the
Fig. 4 a SKCO-1 cells were treated with GO-203 and CP-2 for three days then mitochondrial membrane potential (JC-1) was measured. The results
are expressed as the percentage (mean ± SD of 3 determinations) compared with that obtained for the control. b-c SKCO-1 cells were incubated
with propidium iodide and analyzed by flow cytometry. The results are expressed as the percentage of cells with apoptosis. * p < 0.01, ** p < 0.01,
*** p < 0.001
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protein level [36, 37]. GO-203 treatment of colorectal
cancer cells also resulted in the depletion of TIGAR pro-
tein without any change in mRNA levels. Inhibitors of
PI3K and Akt downregulated TIGAR protein, providing
evidence that these pathways are involved in the depletion
of TIGAR. GO-203 is known to inhibit AKT phosphoryl-
ation [41]. GO-203 further blocks the phosphorylation of
S6K1 in colorectal cancer cells. Rapamycin, an inhibitor
for mTORC1 downregulated TIGAR protein levels.
Similarly Silvestrol, an inhibitor for elF4A RNA helicase
activity, also inhibits TIGAR protein levels. These studies
thus demonstrate that GO-203 induced TIGAR down-
regulation is regulated by PI3K-AKT-S6K1 translation
pathway.
Oxidized glutathione is converted to reduced glutathi-
one by NADPH. With MUC1-C inhibition, NADPH
would be depleted, with subsequent decreases in GSH
levels and increases in ROS. Indeed, GO-203-induced
alteration of redox balance was followed with significant
loss of GSH levels. NAC treatment with GO-203 re-
stored GSH levels and blocked increases in ROS. The
addition of NAC was sufficient to replenish GSH levels.
This finding is consistent with other reports showing
that GO-203 induces ROS production [36, 37]. The elec-
tron transport chain present in the mitochondrial inner
membrane generates ROS. MUC1-C translocates to the
mitochondrial outer membrane in response to stress,
where it attenuates a loss of mitochondrial membrane
potential [14, 15]. Here, we demonstrate that the inhibition
of MUC1-C results in a loss of the mitochondrial mem-
brane potential. Targeting MUC1-C with GO-203 induced
disruption of redox balance was associated with a substan-
tial loss of mitochondrial membrane potential. In concert
with this response, GO-203 was associated with loss of cell
membrane integrity and induction of apoptosis.
MUC1-C is expressed in certain colorectal cancer cells
[39]. The MUC1-C transforming function is dependent
on homodimer formation, which is mediated by a CQC
Fig. 5 GO-203 inhibits cell proliferation and regress tumor growth. a SW480 (Left), LoVo (Center) and COLO-205 (Right) cells were left untreated, or
were treated with 5 μM GO-203 and CP-2 each day for the indicated days. Viable cell numbers were determined by trypan blue exclusion and is
expressed as the mean ± sd of three determinations. Control: Circle; GO-203: Square; CP-2: Triangle. b-c BALB/c nu/nu mice were injected subcutaneously
in the flank with 1 × 107 COLO-205 (b) or SK-CO-1 (c) cells. The mice were pair matched when the tumors were ~100 mm3. b Treatment groups consisted
of 8 mice injected intraperitoneally (ip) with PBS (vehicle control) (Square), 18 mg/kg GO-203(Circle) or 18 mg/kg CP-3 (Triangle) each
day for 28 days. c Treatment groups consisted of 8 mice injected iv with PBS, 6 mg/kg GO-203 each day for 5 days, or 3 mg/kg GO-203 each day for
5 days each week for 2 weeks. Tumor measurements were performed as indicated and mice were weighed twice weekly. There was no weight loss in
any of the groups. d Harvested tissues were stained for TIGAR expression by immunohistochemistry. e Schema depicting the proposed mechanism.
* p < 0.05, ** p < 0.01, *** p < 0.001 as compared to control
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motif present in the cytoplasmic domain of MUC1-C [27].
GO-203 is an inhibitor of MUC1-C, blocks MUC1-C
oligomerization and inhibits the function of MUC1-C as
an intracellular signaling protein [28]. This MUC1 inhibi-
tor has been reported to be effective in inhibiting cell pro-
liferation in-vitro and in xenografts models of breast [28],
prostate [42], lung [43] and certain hematologic malig-
nancy [44]. Here, we show that treatment of MUC1-C-
positive COLO-205 cells with GO-203 is associated with
growth inhibition. By contrast, the MUC1-C inhibitor
GO-203 had no apparent effect on proliferation of
MUC1-C negative colorectal cancer cell lines. The specifi-
city of GO-203 on MUC1-C-positive colorectal cancer
cells is significant, because GO-203 binds to the CQC
motif of MUC1-C and directly blocks MUC1-C function.
The control peptide CP-2, in which the CQC motif has
been changed to an AQA motif [28], does not bind to
MUC1-C and therefore has no effect on the growth of
MUC1-positive colorectal cancer cells.
Treatment of COLO-205 tumors in nude mice responded
to GO-203 treatment with an initial slowing of growth. At
28 days of GO-203 treatment COLO-205 tumor growth
was also slowed after discontinuing dosing and the tumors
regressed completely. Similarly, in the SKCO-1 tumor xeno-
graft model, regression of tumor was found to be evident in
response to a different dose schedule. These findings indi-
cate that GO-203 is effective in inhibiting growth and sur-
vival of MUC1-positive colorectal cancer cells in xenograft
models. The findings also support a GO-203 dose-response
effect with regression of tumors at higher doses (18 mg/kg)
administered for longer periods (28 days). The effectiveness
of GO-203 in colorectal tumor xenografts can be linked to
MUC1 and TIGAR expression in human colon can-
cers. Indeed, TIGAR has been reported to be highly
expressed in human colon cancers with a tumorigenic
phenotype [34, 35]. Confirming this correlation between
MUC1 and TIGAR, inhibition of MUC1-C function
downregulates TIGAR expression in xenograft tissues.
This study supports the importance of MUC1-C in sup-
porting the growth and survival of MUC1-C positive colo-
rectal cancer cells. There has been no previous evidence
that MUC1-C represents a potential target for the treat-
ment of colorectal cancer. Importantly, MUC1-C is known
to interact with β-catenin [9] during cell adhesion. MUC1-
C is also known to bind IKKβ [10] and Rel A p65 [11] and
contributes to constitutive NFκB activation in cancer cells.
It has been reported earlier that NFκB is constitutively acti-
vated in colorectal carcinoma which play important role in
angiogenesis and promoting tumor growth [13]. Therefore,
it is possible that MUC1-C may be involved in activating
β-catenin and NFκB signaling pathways and thereby colo-
rectal cancer progression and hence targeting MUC1-C
with GO-203 could also inhibit these pathways in colorec-
tal cancer cells.
Conclusions
Based on these results, we conclude that the targeting
MUC1-C function by GO-203 downregulates the AKT-
mTORC-S6K1 translation pathway that leads to the deple-
tion of TIGAR translation. GO-203 further downregulates
GSH levels, increases ROS production, decreases mito-
chondrial membrane potential and disrupts cell mem-
brane integrity leading to cell death. Hence, inhibition
of MUC1-C blocks the cellular proliferation and survival
of colorectal cancer cells leading to tumor regression in
colorectal xenografts models and inhibits TIGAR
expression in xenograft tissues. Therefore, colorectal
cancer patients who overexpress MUC1-C may be
candidates for treatment with the MUC1-C inhibitor
alone or in combination therapy with other agents.
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